DOCSLIB.ORG

Report Individual Group Leaders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Report individual group leaders Site visit Hubrecht Institute 10-11 November 2014 - 2 - INDEX Group leader Group name Page Jeroen Bakkers Cardiac Development and Genetics ................................................ 05 Hans Clevers Lgr5 stem cells, Wnt signaling & cancer .......................................... 11 Menno Creyghton Neuro epigenetics ............................................................................ 19 Edwin Cuppen Genome Biology and Medical Genetics ........................................... 25 Eelco de Koning Diabetes and islet neogenesis ......................................................... 33 Wouter de Laat Biomedical Genomics ...................................................................... 39 Jeroen den Hertog Protein-tyrosine phosphatases in development ............................... 47 Jacqueline Deschamps Genetics of morphogenesis during axial elongation in the mouse embryo ............................................................................................. 53 Niels Geijsen Stem Cell Modeling of human genetic disease ................................ 61 Daniele Guardavaccaro Ubiquitin ligases and cancer ............................................................ 67 Jop Kind Spatiotemporal regulation of genomic function ................................ 73 Puck Knipscheer Molecular mechanisms and regulation of DNA repair...................... 77 Rik Korswagen Wnt signaling in development and disease ...................................... 83 Catherine Rabouille Secretion regulation ......................................................................... 89 Catherine Robin Hematopoiesis and stem cells during embryonic development ....... 95 Alexander van Oudenaarden Quantitative biology of development & stem cells ......................... 103 Jacco van Rheenen Cancer Biophysics ......................................................................... 113 Eva van Rooij Molecular Cardiology ..................................................................... 121 - 3 - - 4 - Jeroen Bakkers Key publications (2008-2014) Junker JP, Noël ES, Guryev V, Peterson KA, Shah G, Huisken J, McMahon AP, Berezikov E, Bakkers J* and van Oudenaarden A*. Genome-wide RNA tomography in the zebrafish embryo. *shared corresponding authors. Cell in press. Chetaille P, Côté J, Burkhard S, Houde C, Preuss C, Piché J, Gosset N, Leclerc S, Wünnemann F, Cameron M, Castilloux J, Thibeault M, Gagnon C, Galli A, Tuck A, Hickson G, Amine N, Boufaied I, Lemyre E, Santa Barbara P, Faure S, Jonzon A, Dietz H, Gallo-McFarlane E, Benson W, Zhan SH, Shen Y, Jomphe M, Jones SJM, Bakkers J and Andelfinger G. A human dysrhythmia syndrome affecting heart and gut is associated with mutations in SGOL1. Nat. Genet. in press. Noël ES, Verhoeven M, Lagendijk AK, Tessadori F, Smith K, Choorapoikayil S, den Hertog J, Bakkers J. (2013) A Nodal-independent and tissue-intrinsic mechanism controls heart-looping chirality. Nat. Commun. 4:2754. Mugoni V, Postel R, Catanzaro V, De Luca E, Digilio G, Turco E, Silengo L, Murphy MP, Medana C, Stainier DYR, Bakkers J and Santoro MM. (2013) Ubiad1 Is an Antioxidant Enzyme that Regulates eNOS Activity by CoQ10 Synthesis. Cell 152(3):504-518. Smith K, Chocron S, von der Hardt S, de Pater E, Soufan AT, Bussmann J, Schulte Merker S, Hammerschmidt M and Bakkers J. (2008). Rotation and asymmetric development of the zebrafish heart requires directed migration of cardiac progenitor cells. Dev. Cell 14; 287–297. - 5 - Dr. ir. Jeroen Bakkers Cardiac Development and Genetics Group members Postdocs: Emily Noël, Federico Tessadori, Ina Strate Graduate students: Lotte Koopman, Silja Burkhard, Fabian Kruse, Melanie Laarman Technicians: Sonja Chocron Curriculum vitae group leader Name: Dr. ir. Jeroen Bakkers Date of birth: 13-05-1970 Nationality: Dutch Education/positions 1988-1994 MSc, Wageningen University 1994-2000 PhD, Leiden University 2000-2003 Postdoc, Max-Planck Institute, Freiburg, Germany 2003-2008 Hubrecht Institute, Junior group leader 2008-now Hubrecht Institute, Senior group leader Memberships - Member editorial board Journal of Cardiovascular Development and Disease - President of the Dutch Society of Developmental Biology (DSDB). Awards - 2000 PhD degree with highest distinction (Cum Laude), Leiden University - 2009 NWO/Vidi career grant Other activities • Organizer meetings: 2008, 2011, 2013 National meeting on Cardiac Development, Utrecht. 2008 KNAW colloquium “Cardiac Development, Disease and Stem Cells”, Amsterdam. 2011 1st meeting of the Dutch Society for Developmental Biology (DSDB), Utrecht. Thesis advisor for (graduation date) • Ruben Postel, (May 2008) • Manon Verhoeven, (April 2009) • Emma de Pater, (June 2010) • Anne K. Lagendijk, (December 2011) Invited speaker on meetings (2008-2014) 2008: Weinstein meeting for Cardiovascular Development, Houston, USA 2009: American Heart Association (AHA) Scientific Sessions, Orlando, USA; European Heart Failure meeting (ECS), Nice, France; Joint Meeting 2009 Anatomische Gesellschaft – Nederlandse Anatomen Vereniging, Antwerpen, Belgium; Dutch-German meeting on Cardiovascular research, Hamburg, Germany; Zebrafish PI meeting, Asilomar, USA 2010: EUGeneHeart Symposium, Brussels, Belgium; Basic Cardiovascular Science Meeting of the European Society of Cardiology, Berlin, Germany; Heart Failure Congress (ESC), Berlin, Germany 2011: International Weinstein meeting for Cardiovascular Development, Cincinnati, USA; Zebrafish PI meeting, Asilomar, USA 2012: International Weinstein meeting for Cardiovascular Development, Chicago, USA; Basic Cardiovascular Science Meeting of the European Society of Cardiology, London, UK; ESC Working Group Cardiac Development Meeting, Amsterdam, NL; International meeting on BMP signaling in Development and Disease, Lake Tahoe, USA - 6 - 2013: Zebrafish PI meeting, Asilomar, USA; Zebrafish Development and Disease meeting, Bristol, UK 2014: Zebrafish Disease Models Conference, Madison, USA; Graduate School Student Meeting Münster, Germany; CDBC Spring symposium, Charleston, USA Grants (2008-2014) • 2014 NWO middelgroot (equipment), co-PI € 550,000 • 2013 Nederlandse Hartstichting, co-PI € 250,000 • 2013 ZonMW TOP grant, PI € 290,000 • 2013 CVON CardioVasculair Onderzoek Nederland, co-PI € 200,000 • 2012 CVON CardioVasculair Onderzoek Nederland, co-PI € 450,000 • 2012 NWO PhD fellowship, to S. Burkhard € 200,000 • 2011 NWO ZonMW middelgroot, co-PI € 400,000 • 2009 EU FP7 BIOSCENT, co-PI € 250,000 • 2009 NWO Vernieuwingsimpuls (VIDI), career grant), PI € 600,000 Total: € 3,200,000 Previous research My research is centred on understanding mechanisms of cardiac development and disease using the zebrafish as a model system. During my postdoctoral training I had worked on the role of bone morphogentic protein (BMP), a TGF-ß related growth factor, during gastrulation. I had worked with several zebrafish mutants deficient in BMP signalling components and that displayed cardiac phenotypes that had not been described previously. Considering the advantages of the zebrafish model (good genetic tools, rapid development and transparency of the embryo, and early development independent of functional cardiovascular system), and the early lethality of mouse mutants defective in BMP signalling made me decide to study the role of BMP signalling in cardiac development when starting my own research group at the Hubrecht Institute. This initial work let to the discovery that BMP signalling is required at post-gastrula stages to regulate the asymmetric development of the heart (Chocron et al. (2007) Dev. Biol.). During heart tube formation the inflow pole of the linear heart tube will be positioned left from the embryonic midline after which it forms an S-shaped heart tube with the ventricle moving towards the embryonic right side. Our work demonstrated that BMP signalling is required at two different stages to regulate the asymmetric development of the heart tube; 1) BMP signalling is required to establish correct expression of early laterality markers (such as left-sided Nodal expression) during early somite stages. 2) During late somite stages when asymmetric Nodal expression is established BMP signalling is required for the leftward positioning of the heart tube. To reveal the cell migration behaviour of cardiac progenitor cells during asymmetric heart tube formation I combined confocal time-lapse microscopy with cell tracking tools. Doing so we discovered an asymmetric cell behaviour that results in the clock-wise rotation of the cardiac field during heart tube formation. In addition we found that BMP growth factors can influence cell migration behaviour and regulate the direction of heart tube assembly (Smith et al (2008) Dev. Cell). Other labs have independently confirmed this rotation behaviour and demonstrated that also Nodal growth factors influence migration behaviour of cardiac progenitor cells suggesting a close relation of BMP and Nodal signalling during this process. To allow an unbiased approach to identify components that regulate the left-right axis and/or asymmetric organ development my lab performed several ENU-based forward genetic screens that used alterations in heart laterality (leftward position and directional heart looping) as a read-out (excluding mutants with overt cilia related defects). We screened around 1200 F2 families (about 100.000 embryos) over a period of 2-3 years resulting in the validation of 10 independent mutant lines. Interestingly we found that these mutant lines fall into two different
Recommended publications
  • 2016 Joint Meeting Program

    2016 Joint Meeting Program

    April 15 – 17, 2016 Fairmont Chicago Millennium Park • Chicago, Illinois The AAP/ASCI/APSA conference is jointly provided by Boston University School of Medicine and AAP/ASCI/APSA. Meeting Program and Abstracts www.jointmeeting.org www.jointmeeting.org Special Events at the 2016 AAP/ASCI/APSA Joint Meeting Friday, April 15 Saturday, April 16 ASCI President’s Reception ASCI Food and Science Evening 6:15 – 7:15 p.m. 6:30 – 9:00 p.m. Gold Room The Mid-America Club, Aon Center ASCI Dinner & New Member AAP Member Banquet Induction Ceremony (Ticketed guests only) (Ticketed guests only) 7:00 – 10:00 p.m. 7:30 – 9:45 p.m. Imperial Ballroom, Level B2 Rouge, Lobby Level How to Solve a Scientific Puzzle: Speaker: Clara D. Bloomfield, MD Clues from Stockholm and Broadway The Ohio State University Comprehensive Cancer Center Speaker: Joe Goldstein, MD APSA Welcome Reception & University of Texas Southwestern Medical Center at Dallas Presidential Address APSA Dinner (Ticketed guests only) 9:00 p.m. – Midnight Signature Room, 360 Chicago, 7:30 – 9:00 p.m. John Hancock Center (off-site) Rouge, Lobby Level Speaker: Daniel DelloStritto, APSA President Finding One’s Scientific Niche: Musings from a Clinical Neuroscientist Speaker: Helen Mayberg, MD, Emory University Dessert Reception (open to all attendees) 10:00 p.m. – Midnight Imperial Foyer, Level B2 Sunday, April 17 APSA Future of Medicine and www.jointmeeting.org Residency Luncheon Noon – 2:00 p.m. Rouge, Lobby Level 2 www.jointmeeting.org Program Contents General Program Information 4 Continuing Medical Education Information 5 Faculty and Speaker Disclosures 7 Scientific Program Schedule 9 Speaker Biographies 16 Call for Nominations: 2017 Harrington Prize for Innovation in Medicine 26 AAP/ASCI/APSA Joint Meeting Faculty 27 Award Recipients 29 Call for Nominations: 2017 Harrington Scholar-Innovator Award 31 Call for Nominations: George M.
  • Genomic Misconception

    Genomic Misconception

    1 Genomic Misconception: A fresh look at the biosafety of transgenic and conventional crops. a plea for a process agnostic regulation Klaus Ammann, University of Bern, [email protected] , Neuchâtel, Switzerland December 9, 2012 names. A shorter version has been published in New Biotechnology Ammann, K. (2014), Genomic Misconception: a fresh look at the biosafety of transgenic and conventional crops. A plea for a process agnostic regulation, New Biotechnology, 31, 1, pp. 1-17, http://www.ask-force.org/web/NewBiotech/Ammann-Genomic-Misconception-printed-2014.pdf Abstract: .......................................................................................................................................... 1 1. The scientific basis of the process agnostic regulation ................................................................... 2 2. How the Genomic Misconception was evolving ............................................................................. 4 2.1. How the ‘Genomic Misconception’ was erroneously maintained in the European Regulation and the Cartagena Protocol on Biosafety ....................................................................................... 6 a) Europe, the development of the transatlantic divide with the United States ........................ 6 b) Legislative History of the Cartagena Protocol and its Genomic Misinterpretation of Transgenesis ................................................................................................................................ 8 3. Conclusions ...................................................................................................................................
  • Science & Policy Meeting Jennifer Lippincott-Schwartz Science in The

    Science & Policy Meeting Jennifer Lippincott-Schwartz Science in The

    SUMMER 2014 ISSUE 27 encounters page 9 Science in the desert EMBO | EMBL Anniversary Science & Policy Meeting pageS 2 – 3 ANNIVERSARY TH page 8 Interview Jennifer E M B O 50 Lippincott-Schwartz H ©NI Membership expansion EMBO News New funding for senior postdoctoral In perspective Georgina Ferry’s enlarges its membership into evolution, researchers. EMBO Advanced Fellowships book tells the story of the growth and ecology and neurosciences on the offer an additional two years of financial expansion of EMBO since 1964. occasion of its 50th anniversary. support to former and current EMBO Fellows. PAGES 4 – 6 PAGE 11 PAGES 16 www.embo.org HIGHLIGHTS FROM THE EMBO|EMBL ANNIVERSARY SCIENCE AND POLICY MEETING transmissible cancer: the Tasmanian devil facial Science meets policy and politics tumour disease and the canine transmissible venereal tumour. After a ceremony to unveil the 2014 marks the 50th anniversary of EMBO, the 45th anniversary of the ScienceTree (see box), an oak tree planted in soil European Molecular Biology Conference (EMBC), the organization of obtained from countries throughout the European member states who fund EMBO, and the 40th anniversary of the European Union to symbolize the importance of European integration, representatives from the govern- Molecular Biology Laboratory (EMBL). EMBO, EMBC, and EMBL recently ments of France, Luxembourg, Malta, Spain combined their efforts to put together a joint event at the EMBL Advanced and Switzerland took part in a panel discussion Training Centre in Heidelberg, Germany, on 2 and 3 July 2014. The moderated by Marja Makarow, Vice President for Research of the Academy of Finland.
  • CRISPR-Cas Arxiv:1712.09865V2 [Q-Bio.PE] 26 Mar 2018

    CRISPR-Cas Arxiv:1712.09865V2 [Q-Bio.PE] 26 Mar 2018

    The physicist's guide to one of biotechnology's hottest new topics: CRISPR-Cas Melia E. Bonomo1;3 and Michael W. Deem1;2;3 1Department of Physics and Astronomy, Rice University, Houston, TX 77005, USA 2Department of Bioengineering, Rice University, Houston, TX 77005, USA 3Center for Theoretical Biological Physics, Rice University, Houston, TX 77005, USA Contents 1 Introduction 3 2 Three stages of immunity 4 2.1 Adaptation . 6 2.2 Expression . 7 2.3 Interference . 8 3 Molecular memory cassettes 9 3.1 Timing and origin of acquired spacers . 10 3.2 Experimental studies of spacer diversity . 11 3.3 Modeling spacer diversity in the CRISPR locus . 12 3.4 Effects of spacer acquisition and deletion rates . 14 3.5 Timescale of spacer expression . 17 4 Horizontal gene transfer 17 4.1 Acquisition of CRISPR loci and spacers . 18 arXiv:1712.09865v2 [q-bio.PE] 26 Mar 2018 4.2 CRISPR-Cas restriction of HGT . 19 4.3 Persistent HGT . 20 5 Specificity 21 5.1 Cas specificity and conformational changes . 21 5.2 Identifying CRISPR-Cas PAMs . 24 5.3 Self and non-self discrimination . 25 5.4 Cross-reactivity . 26 5.5 Profiling Cas9 off-target activity . 27 1 6 Evolution and abundance of CRISPR loci 29 6.1 Support for a Lamarckian-type evolution . 29 6.2 Strain divergence . 31 6.3 Selection pressure for survival of the cell . 33 6.4 Impact of effectiveness . 34 7 Cost and regulation of CRISPR Activity 35 7.1 Spacer maintenance considerations . 36 7.2 Turning CRISPR on and off .
  • Steven Henikoff Position

    Steven Henikoff Position

    CURRICULUM VITAE: Steven Henikoff Position: Investigator, Howard Hughes Medical Institute Member, Basic Sciences Division Address: Fred Hutchinson Cancer Research Center 1100 Fairview Ave N. Seattle, Washington 98109-1024 Phone (206) 667-4515; FAX (206) 667-5889 E-mail: [email protected] http://blocks.fhcrc.org/~steveh/ Education 1964-68 University of Chicago, Chicago, Illinois. BS in Chemistry. Research on optical properties of biopolymers, Dr. G. Holzwarth, advisor. 1971-77 Harvard University, Cambridge, Massachusetts. PhD in Biochemistry and Molecular Biology. Dr. M. Meselson, advisor. Thesis: RNA from heat induced puff sites in Drosophila. 1977-80 University of Washington, Seattle, Washington. Postdoctoral fellow in Zoology. Research on position-effect variegation in Drosophila, Dr. C. Laird, advisor, Leukemia Society of America fellow. Professional Experience 1981-85 Fred Hutchinson Cancer Research Center, Seattle, Washington. Assistant Member in Basic Sciences. 1981- University of Washington, Seattle. Affiliate Assistant, Associate and Full Professor of Genetics/Genome Sciences. 1985-88 Fred Hutchinson Cancer Research Center, Seattle, Washington. Associate Member in Basic Sciences. 1988- Fred Hutchinson Cancer Research Center, Seattle, Washington. Member in Basic Sciences. 1990- Investigator, Howard Hughes Medical Institute. Current Research Nucleosome dynamics Transcriptional regulation Centromeric chromatin and centromere evolution Epigenomic technologies Honors (since 2000) 2001 Keynote, 13th International Arabidopsis Conference,
  • Developmental Biology Using Purified Genes

    Developmental Biology Using Purified Genes

    LASKER~KOSHLAND SPECIAL ACHIEVEMENT ESSAY IN MEDICAL SCIENCE AWARD Developmental biology using purified genes Donald D Brown Some history Control Anucleolate Magnesium From the NIH I went to the Pasteur Institute mutant deficient After three years of college I entered the in Paris to study bacterial gene regulation in University of Chicago Medical School in the 1959, the year after the Lac repressor had been fall of 1952 and discovered biochemistry and discovered. Before leaving Bethesda, by the research. Lloyd Kozloff, a member of the greatest luck I learned about a small research bacteriophage group in the Department of institution in Baltimore that was associated Biochemistry, guided my research. While in at that time with the Johns Hopkins Medical medical school I began searching for a future School called the Department of Embryology of research subject, thinking it should be an the Carnegie Institution of Washington. I con- important medically related problem but unex- tacted Jim Ebert, the director, and arranged an plored by what were then the modern methods advanced postdoctoral fellowship after my year of biochemistry. in Paris. It is hard to imagine two more diverse The field of embryology, newly named research institutions. ‘developmental biology’, caught my attention. The Pasteur Institute was at the forefront of Reproductive biology was barely discussed, biology, involved in the founding of molecular and descriptive embryology was taught in two biology. Every day at lunch Jacques Monod, lectures as a part of gross anatomy. In 1953, I François Jacob and André Lwoff presided attended a biochemistry journal club discus- over an exciting discussion usually augmented Figure 1 Comparison of control (left), anucleolate sion of the Watson-Crick Nature paper describ- by a prominent visitor.
  • Enhancers, Enhancers – from Their Discovery to Today’S Universe of Transcription Enhancers

    Enhancers, Enhancers – from Their Discovery to Today’S Universe of Transcription Enhancers

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by RERO DOC Digital Library Biol. Chem. 2015; 396(4): 311–327 Review Walter Schaffner* Enhancers, enhancers – from their discovery to today’s universe of transcription enhancers Abstract: Transcriptional enhancers are short (200–1500 one had ever postulated their existence, simply because base pairs) DNA segments that are able to dramatically there seemed to be no need for them. Now that introns boost transcription from the promoter of a target gene. and enhancers are part of the scientific world, one cannot Originally discovered in simian virus 40 (SV40), a small imagine how higher forms of life could ever have evolved DNA virus, transcription enhancers were soon also found without the multitude of tailored proteins that can be in immunoglobulin genes and other cellular genes as produced by alternative splicing, or without the sophisti- key determinants of cell-type-specific gene expression. cated patterns of remote transcription control by enhanc- Enhancers can exert their effect over long distances of ers. Indeed, the complexity of an organism is primarily thousands, even hundreds of thousands of base pairs, determined by the variety of gene regulation mechanisms, either from upstream, downstream, or from within a tran- rather than by the number of genes. scription unit. The number of enhancers in eukaryotic genomes correlates with the complexity of the organism; a typical mammalian gene is likely controlled by several enhancers to fine-tune its expression at different devel- The holy grail opmental stages, in different cell types and in response In the fall of 1978, I returned to Zurich University from to different signaling cues.
  • Steven Henikoff Position

    Steven Henikoff Position

    CURRICULUM VITAE: Steven Henikoff Position: Investigator, Howard Hughes Medical Institute Member, Basic Sciences Division Address: Fred Hutchinson Cancer Research Center 1100 Fairview Ave N. Seattle, Washington 98109-1024 Phone (206) 667-4515; FAX (206) 667-5889 E-mail: [email protected] http://research.fhcrc.org/henikoff/en.html Education 1964-68 UniversitY of Chicago, Chicago, Illinois. BS in ChemistrY. Research on optical properties of biopolymers, Dr. G. Holzwarth, advisor. 1971-77 Harvard UniversitY, Cambridge, Massachusetts. PhD in BiochemistrY and Molecular BiologY. Dr. M. Meselson, advisor. Thesis: RNA from heat induced puff sites in Drosophila. 1977-80 UniversitY of Washington, Seattle, Washington. Postdoctoral fellow in Zoology. Research on position-effect variegation in Drosophila, Dr. C. Laird, advisor, Leukemia SocietY of America fellow. Professional Experience 1981-85 Fred Hutchinson Cancer Research Center, Seattle, Washington. Assistant Member in Basic Sciences. 1981- UniversitY of Washington, Seattle. Affiliate Assistant, Associate and Full Professor of Genetics/Genome Sciences. 1985-88 Fred Hutchinson Cancer Research Center, Seattle, Washington. Associate Member in Basic Sciences. 1988- Fred Hutchinson Cancer Research Center, Seattle, Washington. Member in Basic Sciences. 1990- Investigator, Howard Hughes Medical Institute. Current Research Nucleosome dYnamics Transcriptional regulation Centromeric chromatin and centromere evolution Epigenomic technologies Ongoing Funding Howard Hughes Medical Institute Investigator 04/1/1990
  • DNA Methylation Patterns and Cancer

    DNA Methylation Patterns and Cancer

    restriction/modification system, which brought Werner Arber, Daniel Nathans and Hamilton Smith the 1978 Nobel Prize in Physiology or Medicine, and made restriction enzymes the primary tools of Charles Rodolphe Brupbacher Foundation molecular biology. Four decades have passed since then, but the role of 5-methylcytosine in eukaryotic DNA metabolism is still shrouded in mystery. We know that the sperm methylation pattern is largely The erased after fertilization and that methylation is gradually reintroduced Charles Rodolphe Brupbacher Prize during embryogenesis and differentiation, but the processes that for Cancer Research 2017 regulate the cell type- and tissue-specific methylation patterns remain is awarded to to be elucidated. We have also learned that DNA can be not only methylated, but also demethylated, and that aberrant methylation can lead to disease - including cancer. Again, how these processes are regulated remains to be discovered. However, we have learnt a great Sir Adrian Peter Bird, deal about 5-methylcytosine metabolism during the past three decades and much of our knowledge came from the laboratory of Adrian Bird. PhD Adrian spent his doctoral and postdoctoral time in Max Birnstiel’s for his contributions to our understanding laboratory, first in Edinburgh and then in Zurich, studying the amplification of ribosomal DNA in Xenopus laevis. In this organism, of the role of DNA methylation in genomic rDNA in somatic tissues is highly methylated, while the development and disease extrachromosomal amplicons are unmethylated. When he returned to Edinburgh to establish his own group, Adrian set out to study The President The President of the Foundation of the Scientific Advisory Board the methylation pattern of these loci using the newly-available methylation-sensitive restriction enzymes.
  • A1983qz35500002

    A1983qz35500002

    — — — CC/NUMBER 31 This Week’s Citation Classic AUGUST 1,1983 [irown I) D & Dawld I B. Specific gene amplification in oocytes. I Science 160:272-80, 1968. IDepartment of Embryology, Carnegie Institution of Washington, Baltimore, MD) The genes for 18S and 28S ribosomal RNA are “An international meeting on the nucleo- amplified specifically in oocyte nuclei of amphib- lus was held in Montevideo, Uruguay, in iarss forming more than a thousand nucleoli in each nucleus. These extra genes support enormous 1965. Without a doubt, the highlight of that rates of ribosomal RNA synthesis during meeting was Birnstiel’s demonstration of oogenesis. [The SCI® indicates that this paper has how he had used physicochemical tech4- been cited in over 530 publications since 1968.1 niques to isolate the ribosomal RNA genes. At that conference I heard Oscar Miller, then a staff member at the Oak Ridge Labo- Donald D. Brown ratories, describe the presence of circular chromosomes in the many nucleoli of frog Department of Embryology 5 Carnegie Institution of Washington oocyte nuclei. I knew instantly from the Baltimore, MD 21210 previous correlations of ribosomal RNA genes and the nucleolus that these must be July 7, 1983 extra copies of ribosomal RNA genes. lgor Dawid, a fellow staff member at Carnegie, “This paper and one published indepen1 - and I set out to prove this idea. dently at the same time by Joseph Gall “A key experiment described in our Sci- were the first to demonstrate specific gene ence paper depended upon the isolation by amplification — an event programmed into hand of ten thousand nuclei from Xenopus the development of a cell.
  • Career Jump for Professor Kim Nasmyth

    Career Jump for Professor Kim Nasmyth

    Press Release March 24th, 2004 Career jump for Professor Kim Nasmyth Prof. Kim Nasmyth, Director of the IMP Vienna, Boehringer Ingelheim’s Basic Research Institute, to take up prestigious Oxford Chair. The Research Institute of Molecular Pathology (IMP) which belongs to the international pharmaceutical company Boehringer Ingelheim has already served as starting point or stepping stone for several internationally outstanding scientific careers. Now a call from one of the best Universities in Europe has reached IMP Director Kim Nasmyth. In January 2006 he will take over the Whitley Chair of Biochemistry at the University of Oxford from Edwin Southern. One year later he will follow Raymond Dwek as Head of the Department of Biochemistry. He will then lead one of the largest departments of Biochemistry in the western world with approximately 850 employees and students. The Whitley Chair has an excellent reputation: founded in 1920, the position has been held by a succession of outstanding scientists, including Nobel laureates Hans Krebs and Rodney Porter. “The appointment certainly honours me personally but is also proof of the IMP’s excellent reputation in the scientific world” says Nasmyth. Prof. Kim Nasmyth Director of the Research Institute of Molecular Pathology (IMP) (Foto: IMP). Dr. Dr. Andreas Barner – vice Chairman of the Board of Directors of Boehringer Ingelheim and responsible for the corporate divisions Pharma Research, Development and Medicine, sees Prof. Nasmyth’s appointment as confirmation of the internationally- recognised outstanding research performed at the IMP: “The Research Institute of Molecular Pathology is a major contribution from Boehringer Ingelheim to basic research at the highest level and has achieved world renown with outstanding scientists working there under Prof.
  • FOR IMMEDIATE RELEASE Sean J. Morrison Assumes Leadership Of

    FOR IMMEDIATE RELEASE Sean J. Morrison Assumes Leadership Of

    FOR IMMEDIATE RELEASE Sean J. Morrison Assumes Leadership of the International Society for Stem Cell Research Term Begins Immediately Following the ISSCR Annual Meeting, June 24-27, 2015, Stockholm, Sweden CHICAGO (June 15, 2015) — The International Society for Stem Cell Research (ISSCR) is pleased to announce Sean J. Morrison, Children’s Research Institute at UT Southwestern Medical Center, as incoming president of the ISSCR board of directors, immediately following the ISSCR’s annual meeting, June 24-27, 2015. Morrison will serve as president for one year and succeeds Rudolf Jaenisch, Whitehead Institute for Biomedical Research and MIT. The role of president elect will be filled by Sally Temple, Neural Stem Cell Institute, and the role of vice president will be filled by Hans Clevers, Hubrecht Institute. “It is an exciting time to be a stem cell researcher. There are unprecedented opportunities for scientific breakthroughs, as well as new treatments for incurable diseases,” Morrison said. “The field is beginning to deliver on its promise, with many exciting new therapies going into clinical trials. But this research must move forward safely, ethically, and effectively while contending with limited funding for biomedical research and regulatory challenges. The ISSCR will continue to provide a strong international voice for stem cell researchers, working globally to accelerate the science and the development of new therapies. The ISSCR will also be an authoritative and credible resource for policymakers and patients to promote the development of effective policies and the dissemination of safe and effective therapies.” Morrison has been actively involved with ISSCR since its inception in 2002 and has served in leadership roles on the board of directors or on the executive committee since 2004.